Phaseline

Targets › WEE1

WEE1 (Wee1-like protein kinase): drug programs, companies and trials

3 programs from 3 companies in 17 trials: 10 Phase 2, 6 Phase 1, 1 Phase 3; Oncology; next expected readout Nov 2026.

Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs…. (UniProt, P30291)

Open in Phaseline: the race on WEE1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis PharmaceuticalsAzenosertib
Serine/threonine-protein kinase WEE1 inhibitor
WEE1Phase 3Ovarian Cancer; High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer; Solid Tumor; Uterine Serous Carcinoma …Dec 2026
AstraZenecaAdavosertib (AZD1775)
Serine/threonine-protein kinase WEE1 inhibitor
WEE1Phase 2Metastatic Triple Negative Breast Cancer; Muscle Invasive Bladder Cancer; Prostate Cancer; Advanced Lymphoma …Nov 2026
Aprea TherapeuticsAPR-1051
WEE1 inhibitor
WEE1Phase 1Advanced Solid TumorJun 2027

Conditions

Advanced Lymphoma (2) Metastatic Triple Negative Breast Cancer (1) Muscle Invasive Bladder Cancer (1) Prostate Cancer (1) Recurrent Fallopian Tube Carcinoma (1) Ovarian Brenner Tumor (1) Clear Cell Renal Cell Carcinoma (1) Uterine Cancer (1) Clinical Stage III Esophageal Adenocarcinoma AJCC v8 (1) Advanced Malignant Solid Neoplasm (1) Ovarian Cancer (1) High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer (1)

Modalities

mixed (2), small molecule (1)

Companies

AstraZeneca (1) K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals (1) Aprea Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.